IL137550A0 - Epothilone compositions - Google Patents

Epothilone compositions

Info

Publication number
IL137550A0
IL137550A0 IL13755099A IL13755099A IL137550A0 IL 137550 A0 IL137550 A0 IL 137550A0 IL 13755099 A IL13755099 A IL 13755099A IL 13755099 A IL13755099 A IL 13755099A IL 137550 A0 IL137550 A0 IL 137550A0
Authority
IL
Israel
Prior art keywords
epothilone
compositions
epothilone compositions
Prior art date
Application number
IL13755099A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL137550(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL137550A0 publication Critical patent/IL137550A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13755099A 1998-02-05 1999-02-03 Epothilone compositions IL137550A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds
PCT/EP1999/000702 WO1999039694A2 (en) 1998-02-05 1999-02-03 Compositions containing organic compounds

Publications (1)

Publication Number Publication Date
IL137550A0 true IL137550A0 (en) 2001-07-24

Family

ID=26313062

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13755099A IL137550A0 (en) 1998-02-05 1999-02-03 Epothilone compositions
IL137550A IL137550A (en) 1998-02-05 2000-07-27 Apothelial compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137550A IL137550A (en) 1998-02-05 2000-07-27 Apothelial compositions

Country Status (37)

Country Link
US (5) US20030203876A1 (es)
EP (1) EP1052974B1 (es)
JP (2) JP4644364B2 (es)
KR (3) KR100669174B1 (es)
CN (2) CN100396276C (es)
AR (1) AR017979A1 (es)
AT (1) ATE431733T1 (es)
AU (1) AU753519B2 (es)
BE (1) BE1012140A3 (es)
BR (1) BR9907647B1 (es)
CA (1) CA2320182C (es)
CL (1) CL2003002786A1 (es)
CO (1) CO4920246A1 (es)
CY (1) CY1109311T1 (es)
CZ (1) CZ303168B6 (es)
DE (1) DE69940904D1 (es)
DK (1) DK1052974T3 (es)
ES (1) ES2324378T3 (es)
FR (1) FR2774909B1 (es)
HK (1) HK1033809A1 (es)
HU (1) HUP0101564A3 (es)
ID (1) ID26549A (es)
IL (2) IL137550A0 (es)
IT (1) IT1313549B1 (es)
MX (1) MXPA00007681A (es)
MY (1) MY125921A (es)
NO (2) NO329376B1 (es)
NZ (1) NZ506389A (es)
PE (1) PE20000272A1 (es)
PL (1) PL201329B1 (es)
PT (1) PT1052974E (es)
RU (1) RU2214246C2 (es)
SI (1) SI1052974T1 (es)
SK (2) SK287775B6 (es)
TR (1) TR200002299T2 (es)
TW (1) TW457095B (es)
WO (1) WO1999039694A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
NZ335383A (en) 1996-11-18 2000-10-27 Biotechnolog Forschung Gmbh Epothilone C,D,E and F for plant protection and cytostatic effects shown in kidney cells
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CA2350189A1 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
JP4633331B2 (ja) * 2001-01-25 2011-02-16 ブリストル−マイヤーズ スクイブ カンパニー 癌治療のためのエポチロン類似体の投与方法
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2438598A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Epothilone derivatives for the treatment of refractory tumors
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
JP2004529904A (ja) 2001-03-14 2004-09-30 ブリストル−マイヤーズ　スクイブ　カンパニー 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ
SI1372650T1 (sl) * 2001-03-19 2009-04-30 Novartis Ag Kombinacije, ki obsegajo antidiaroično sredstvo in epotilon ali epotilonski derivat
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
RU2346686C2 (ru) 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
MXPA04012444A (es) * 2002-06-10 2005-04-19 Novartis Ag Combinaciones que comprenden epotilonas y sus usos farmaceuticos.
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
SI1767535T1 (sl) 2002-08-23 2010-03-31 Sloan Kettering Inst Cancer Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003275068B2 (en) 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
WO2004032866A2 (en) 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Therapeutic formulations
CA2501717C (en) * 2002-10-15 2012-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
US20040152708A1 (en) 2002-11-07 2004-08-05 Yong Li Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1710244A4 (en) * 2004-01-29 2009-06-17 Eisai R&D Man Co Ltd METHOD FOR STABILIZING A MACROLIDE COVERAGE
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
MX2009001635A (es) 2006-08-16 2009-02-23 Novartis Ag Forma de cristal de epotilona b y su uso en composiciones farmaceuticas.
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
MX2020007270A (es) * 2017-09-27 2020-08-17 Novartis Ag Formulacion parenteral que comprende siponimod.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
ATE218556T1 (de) * 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs

Also Published As

Publication number Publication date
SK287487B6 (sk) 2010-11-08
ID26549A (id) 2001-01-18
JP2010090147A (ja) 2010-04-22
PE20000272A1 (es) 2000-04-17
MY125921A (en) 2006-08-30
US20060127423A1 (en) 2006-06-15
BE1012140A3 (fr) 2000-05-02
AU753519B2 (en) 2002-10-17
CA2320182C (en) 2008-11-25
DE69940904D1 (de) 2009-07-02
CN1623543A (zh) 2005-06-08
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
ATE431733T1 (de) 2009-06-15
KR20080016756A (ko) 2008-02-21
NO329376B1 (no) 2010-10-04
PT1052974E (pt) 2009-08-07
IT1313549B1 (it) 2002-09-09
IL137550A (en) 2010-06-30
TR200002299T2 (tr) 2000-11-21
KR20010040534A (ko) 2001-05-15
US20080221065A1 (en) 2008-09-11
SI1052974T1 (sl) 2009-10-31
NZ506389A (en) 2003-07-25
CA2320182A1 (en) 1999-08-12
CZ303168B6 (cs) 2012-05-09
WO1999039694A3 (en) 1999-09-23
US20030203876A1 (en) 2003-10-30
DK1052974T3 (da) 2009-08-10
SK11702000A3 (sk) 2001-01-18
AU2722699A (en) 1999-08-23
FR2774909B1 (fr) 2000-07-28
JP2002502810A (ja) 2002-01-29
SK287775B6 (sk) 2011-09-05
TW457095B (en) 2001-10-01
JP4644364B2 (ja) 2011-03-02
US20070060627A1 (en) 2007-03-15
BR9907647A (pt) 2000-11-14
PL201329B1 (pl) 2009-03-31
CN1292683A (zh) 2001-04-25
WO1999039694A2 (en) 1999-08-12
MXPA00007681A (es) 2003-07-14
CY1109311T1 (el) 2014-07-02
ITMI990208A1 (it) 2000-08-04
US20110124691A1 (en) 2011-05-26
EP1052974A2 (en) 2000-11-22
HUP0101564A2 (hu) 2001-11-28
CZ20002834A3 (cs) 2000-11-15
HUP0101564A3 (en) 2002-06-28
CO4920246A1 (es) 2000-05-29
KR100669174B1 (ko) 2007-01-17
HK1033809A1 (en) 2001-09-28
NO20003930L (no) 2000-10-04
ES2324378T3 (es) 2009-08-05
EP1052974B1 (en) 2009-05-20
CN100396276C (zh) 2008-06-25
CL2003002786A1 (es) 2005-02-04
AR017979A1 (es) 2001-10-24
BR9907647B1 (pt) 2014-04-01
RU2214246C2 (ru) 2003-10-20
NO20100302L (no) 2000-10-04
NO20003930D0 (no) 2000-08-03
FR2774909A1 (fr) 1999-08-20

Similar Documents

Publication Publication Date Title
IL137550A0 (en) Epothilone compositions
AP2000001874A0 (en) Cellecoxib compositions
GB9917982D0 (en) Compositions
GB9811377D0 (en) Compositions
EP0994183A4 (en) FUNCTIONAL COMPOSITIONS
GB9924268D0 (en) Compositions
GB9809058D0 (en) Composition
GB9812119D0 (en) Composition
GB9828861D0 (en) Compositions
GB9806788D0 (en) Composition
GB9806793D0 (en) Composition
GB2339693B (en) Anti-mollusc compositions
GB9805782D0 (en) Compositions
GB9806810D0 (en) Compositions
GB9827291D0 (en) Compositions
GB9812818D0 (en) Dentfrice compositions
GB0016470D0 (en) Compositions
GB2336535B (en) Compositions
GB9809347D0 (en) Compositions
GB9804041D0 (en) Composition
GB9827690D0 (en) Compositions
GB9816050D0 (en) Compositions
GB9806791D0 (en) Composition
GB9818278D0 (en) Compositions
GB9803982D0 (en) Composition